Supernus Pharmaceuticals (SUPN) investor relations material

Product performance and demand trends

• March saw a strong rebound in prescriptions and prescriber activity after resolving supply constraints, with some metrics surpassing pre-constraint levels.

• Demand remained robust during supply issues, with physicians continuing to submit patient forms and maintain waitlists.

• Approximately 500 new patient forms were received in Q4 2025 and 400 in Q1 2026, reflecting steady demand.

• There are currently about 970 forms in process, with 400 new and 570 in the queue, managed by dedicated teams at various stages.

• Processing inefficiencies and insurance requirements mean it takes several weeks for a form to convert to a shipment.

Commercial strategy and market expansion

• The product launched a year ago, with 2,200 enrollment forms from 645 prescribers, averaging 3-4 forms per prescriber.

• Many prescribers are still early adopters, with efforts focused on increasing both the number of prescribers and prescription depth.

• Commercial strategy includes challenging physicians to expand use among eligible patients and presenting the product as a clear option.

Supply chain and capacity planning

• Guidance for 2026 is $45–$70 million, requiring 700–800 patients on therapy year-round.

• Current supplier can meet projected demand; guidance will be reassessed in August after six months of data.

• Second supplier submission is planned for Q3 2026, with FDA review expected to take 6–9 months, targeting mid-2027 for approval.

• Capacity planning includes bringing a third supplier online to support anticipated growth beyond 2027.